AI reads biopsy slides to predict chemo success in breast cancer

NCT ID NCT07327970

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new AI tool called Ataraxis that analyzes images of breast cancer biopsy slides along with basic patient information to predict how well the cancer will respond to chemotherapy before surgery. The study will enroll 150 adults with early-stage breast cancer who are scheduled for chemotherapy. The goal is to see if the AI test can be easily used in routine care and whether it accurately predicts treatment outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ataraxis multi-modal AI prognostic test
What this could lead to
If successful, this AI test could help doctors better predict which breast cancer patients will respond to chemotherapy, leading to more personalized treatment plans.
What could go wrong
This is an early-stage observational study with only 150 participants. The AI test is not yet proven to improve patient outcomes, and results may not apply to all breast cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea

    RECRUITING

    Incheon, 21431, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.